bioRxivMicrobiologyPreprint
Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
B. Kovacech, L. Fialova, P. Filipcik, M. Zilkova, R. Skrabana, N. Paulenka-Ivanovova, A. Kovac, D. Palova, G. Paulikova Rolkova, K. Tomkova, N. Turic Csokova, K. Markova, M. Skrabanova, K. Sinska, N. Basheer, P. Majerova, J. Hanes, V. Parrak, M. Prcina, O. Cehlar, M. Cente, J. Piestansky, M. Fresser, M. Novak, M. Slavikova, , E. Kontsekova
Abstract
Recently emerged SARS-CoV-2 variants show resistance to some antibodies that were authorized for emergency use. We employed hybridoma technology combined with authentic virus assays to develop second-generation antibodies, which were specifically selected for their ability to neutralize new variants of SARS-CoV-2. AX290 and AX677, two monoclonal antibodies with non-overlapping epitopes, exhibit subnanomolar or nanomolar affinities to the receptor binding domain of the viral Spike protein carrying amino acid substitutions N501Y, N439K, E484K, K417N, and a combination N501Y/E484K/K417N found in the circulating virus variants. The antibodies showed excellent neutralization of an authentic SARS-CoV-2 virus representing strains circulating in Europe in spring 2020 and also the variants of concern B.1.1.7 and B.1.351. Finally, the combination of the two antibodies prevented the appearance of escape mutations of the authentic SARS-CoV-2 virus. The neutralizing properties were fully reproduced in chimeric mouse-human versions, which may represent a promising tool for COVID-19 therapy.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Y. Weisblum, F. Schmidt, … P. D. Bieniasz·bioRxiv·Jul 21, 2020
- Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
H. Cho, K. K. Gonzales-Wartz, … J. Tan·bioRxiv·Apr 1, 2021
- The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
E. Makdasi, A. Zvi, … R. Rosenfeld·bioRxiv·Apr 1, 2021
- Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains
- Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
L. Liu, R. G. Casner, … D. D. Ho·bioRxiv·Apr 8, 2023
- Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617